Glaukos is aiming to tackle the glaucoma market with micro-devices that include the iStent and iDose devices, CEO Tom Burns said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco.
“Our mission is aspirational,” he said. “As a company we are seeking to transform glaucoma therapy, and in doing so we want to transform ourselves into a hybrid surgical-pharmaceutical-medical device company that is creating powerful platforms in sustained pharmaceutical therapy, medical devices and diagnostic platforms.”
More than 500,000 iStent and iStent inject devices
Uncategorized